In a laboratory in Hefei, China, a team of researchers has identified a small molecule that could rewrite the prognosis for one of the deadliest forms of lung cancer. The compound, called IHMT-15137, was developed by scientists at the Institute of Health and Medical Technology, part of the Hefei Institutes of Physical Science at the Chinese Academy of Sciences, and early results suggest it may help patients overcome a stubborn form of treatment resistance that has long confounded oncologists.
Small cell lung cancer accounts for roughly 15 percent of all lung cancer cases worldwide. It grows quickly and is often caught at an advanced stage. The standard treatment is chemotherapy, but many patients develop resistance within months, leaving doctors with few effective options. The five-year survival rate hovers around just 7 percent.
The research team, led by Professor Liu Qingsong, focused on understanding why the cancer cells resist chemotherapy so effectively. They discovered that two proteins — BMX and E2F1 — are unusually active in drug-resistant tumors. BMX stabilizes E2F1, allowing cancer cells to keep growing, repairing themselves, and spreading even when bombarded with chemotherapy drugs. This mechanism, the researchers found, is a key driver of treatment failure.
Working from this insight, the team designed IHMT-15137 to block BMX directly. In laboratory tests, combining the molecule with cisplatin — a common chemotherapy drug — produced powerful antitumor effects in resistant cancer cells and in patient-derived tumor models. The dual approach slowed tumor growth, triggered cancer cell death, and did so with minimal side effects in animal studies.
Associate Professor Qi Shuang, who helped lead the investigation, said the findings open a new avenue for tackling chemoresistance earlier in the disease process. "Our findings suggest a new way to overcome chemotherapy resistance in small cell lung cancer by targeting key proteins early in the pathway," she said.
The study was published in the journal Signal Transduction and Targeted Therapy. While the compound has not yet been tested in humans, the researchers say the results provide a strong foundation for further development. For a cancer that has seen limited treatment advances over decades, the discovery offers a meaningful reason for cautious optimism.